Our foundation began providing a new HLA genome-edited iPS cell stock (“genome-edited line”) on 02 March 2026. The newly available genome-edited strains are clinical-grade iPS cells generated from umbilical cord blood-derived iPS cells with clinical track records. Using CRISPR-Cas9 genome editing technology, the HLA-A gene, the HLA-B gene, and the CIITA gene-which regulates HLA-Class II expression- have been deleted, while HLA-C gene is retained. Genome-edited strains derived from peripheral blood have also been made available previously.

For further details, please refer to the HLA Genome-Edited iPS Cell Stock page.
https://www.cira-foundation.or.jp/e/provision-of-ips-cells/genome-edited/

By expanding the range of iPS cell types we provide, we anticipate to support the research and development activities of a broader range of research institutions and companies, thereby further advancing the evaluation of safety and efficacy in regenerative medicine using HLA genome-edited iPS cell stocks.